基于树突状细胞的疫苗接种策略:一个不断演变的范式
本文综述了树突状细胞(DC)在肿瘤微环境中的作用、基于DC的疫苗在免疫治疗中的应用与当前临床使用情况、限制其抗癌疗效的挑战以及开发成功抗肿瘤DC疫苗的未来方向。
要点
- DC是适应性免疫应答的有效启动者,在免疫治疗中起关键作用。
- 多种DC疫苗临床试验已证明可诱导抗肿瘤免疫应答并延长生存期。
- 当前仍存在限制DC疫苗抗癌疗效的挑战,需探索未来发展方向。
核心结论
- 基于DC的疫苗接种策略是一个不断演变的范式,临床试验已显示其可诱导抗肿瘤免疫应答并延长生存期,但仍面临限制疗效的挑战。
研究设计与样本
- 综述,总结当前关于DC及其在肿瘤微环境中作用、在免疫治疗中的应用与当前临床使用、限制疗效的挑战及未来方向的文献。
主要发现
- DC是适应性免疫应答的有效启动者,在免疫治疗的发展和成功中起关键作用。
- 多种DC疫苗的临床试验已证明可诱导抗肿瘤免疫应答并延长多种癌症的生存期。
局限性
- 原文报告当前仍存在限制DC疫苗抗癌疗效的挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant gliomas (MG), tumors of glial origin, are the most commonly diagnosed primary intracranial malignancies in adults. Currently available treatments have provided only modest improvements in overall survival and remain limited by inevitable local recurrence, necessitating exploration of novel therapies. Among approaches being investigated, one of the leading contenders is immunotherapy, which aims to modulate immune pathways to stimulate the selective destruction of malignant cells. Dendritic cells (DCs) are potent initiators of adaptive immune responses and therefore crucial players in the development and success of immunotherapy. Clinical trials of various DC-based vaccinations have demonstrated the induction of anti-tumor immune responses and prolonged survival in the setting of many cancers. In this review, we summarize current literature regarding DCs and their role in the tumor microenvironment, their application and current clinical use in immunotherapy, current challenges limiting their efficacy in anti-cancer therapy, and future avenues for developing successful anti-tumor DC-based vaccines.
引用
- Filley AC, Dey M. Dendritic cell based vaccination strategy: an evolving paradigm. J Neurooncol. 2017. PMID: 28434112. doi:10.1007/s11060-017-2446-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。